In Georgia, as Biden mentioned in his speech, Democrats are feeling bullish. Many more votes are yet to come in from the Atlanta area; in DeKalb County, for instance, one of the state’s largest, early in-person votes had not even begun to be counted until last night. In many of these still-uncalled states, Trump holds the lead in terms of ballots counted — but that could easily change as more mail-in ballots and some in-person votes continue to be tabulated.- Advertisement – But Democrats also picked up two Senate seats, in Colorado and Arizona, and close races remain uncalled in North Carolina, Georgia, Michigan and Maine — most of them potential Democratic pickups. The party’s path to a Senate majority may have narrowed somewhat, but the fate of the chamber, it’s safe to say, still hangs in the balance.Where we’re atBased on the states that have already been declared, Biden needs 43 more electoral votes to get to the golden number of 270, and Trump needs 57.The three Northern states that flipped for Trump in 2016 — Wisconsin, Michigan and Pennsylvania — remain uncalled. So do North Carolina and Georgia, both of which went for him in 2016 but have been heavily targeted by Democrats this cycle, and both of which are double-whammies: They have contested Senate races hitched to the presidential contest. Nov. 4, 2020, 6:08 a.m. ET “I’m here to tell you tonight, we believe we’re on track to win this election,” he said. “We knew because of the unprecedented early vote and the mail-in vote, it was going to take a while. We’re going to have to be patient until the hard work of tallying the votes is finished. And it ain’t over until every vote is counted, every ballot is counted.”Republicans yesterday did win closely contested Senate races in at least two states, Alabama and Iowa, and flipped at least six House seats, giving them a four-seat net gain in that chamber so far.- Advertisement – Updated – Advertisement – – Advertisement –
Democrats still remained hopeful about the races in Georgia. The Rev. Dr. Raphael G. Warnock, a Democrat, was headed for a January runoff against Senator Kelly Loeffler, the appointed Republican, in a special election to replace Senator Johnny Isakson, who retired in late 2019 citing health problems. Jon Ossoff, 33, a documentary filmmaker, was in a tight race to unseat Mr. Perdue, which could also end up in a runoff if neither cleared the 50 percent threshold required under Georgia law to win outright.Both parties had other outstanding targets, but they were considered stretches. For Republicans, the best option was Michigan, where John James, a Black Iraq war veteran who ran for the Senate unsuccessfully in 2018, was trying to unseat Senator Gary Peters. Democrats still believed they had an outside shot of defeating Senator Dan Sullivan in Alaska.Catie Edmondson contributed reporting.- Advertisement – Among all the victories for Senate Republicans, Ms. Collins’s stood out as the most remarkable. Facing an onslaught of liberal outrage over her 2018 vote to confirm Justice Brett M. Kavanaugh to the Supreme Court amid accusations of sexual assault, she trailed the Democrat, Sara Gideon, the speaker of the Maine House of Representatives, in the race’s closing weeks. She also faced a potential revolt by the state’s most conservative voters unhappy with her frequent criticism of Mr. Trump.In the end, she proved she was one of the only senators in the country still able to significantly outrun the top of the ticket, winning her fifth term even as Mr. Trump lost badly in Maine to Mr. Biden.- Advertisement – – Advertisement – Still, already eying a 2022 Senate election on more difficult turf for Republicans, Mr. McConnell suggested there were reasons for the party to worry, as well.Speaking to reporters after his own commanding victory in Kentucky, he said Republicans had pressing work to do to win back the support of women and college-educated voters, as well as to bolster their fund-raising apparatus, which has trailed Democrats’ juggernaut, ActBlue.“I am disturbed by the loss of support in the suburbs nationwide,” Mr. McConnell said.- Advertisement –
Meanwhile, Neville thinks only injury can stop Kane breaking every record in the game after the England striker scored his 150th Premier League goal in Spurs’ victory over West Brom.It followed his 200th goal for Spurs in the Europa League in midweek, and Neville insists England are lucky to have him in their ranks.“The only thing that can stop Harry Kane doing everything in the game, breaking every record, is injury,” Neville said. “It would be something that would alarm Chelsea fans, Manchester United fans and Arsenal fans. It would be one of the great stories, because Tottenham don’t win leagues!“He’s got the forward players to do it. You think of the strike force and the goal – it’s incredible.” Harry Kane became the third fastest player to score 150 Premier League goals when he got the late winner in Tottenham’s 1-0 win over West Brom The final word from Neville’s podcast this week goes to his former club Manchester United.Ole Gunnar Solskjaer’s side picked up a much-needed win at Everton on Saturday lunchtime, and while Neville thinks they deserved their win at Goodison Park, he believes inconsistency will continue to hurt them as they look to push up the table.He said: “I was glued to the TV from 11.30am yesterday morning, thinking about the game, thinking about the previous week, and you just think: ‘We need a performance here, Ole needs a performance, the club need a performance, players need a performance.’ Image:Neville praised the work of Brendan Rodgers at Leicester ‘England lucky to have Kane’ Gary Neville insists Jose Mourinho has the attacking players at his disposal at Tottenham to deliver the north London club the Premier League title, but the former Manchester United defender is still not convinced they can do it.Spurs moved to the top of the Premier League for a short while on Sunday after Hary Kane’s 88th-minute header snatched a 1-0 victory at West Brom.- Advertisement – 3:12 Image:Bruno Fernandes celebrates after equalising for Manchester United at Everton ‘Rodgers an outstanding coach’ – Advertisement – Carra: I’d love to see Jose win againSpeaking on Monday Night Football a few weeks back, Sky Sports pundit Jamie Carragher admitted he would relish the prospect of Jose Mourinho getting his hands back on the Premier League trophy after being subjected to criticism in the five years since his last title-winning campaign.“I obviously want Liverpool to win the league, but if someone else were to win it, I’d love to see Jose Mourinho win again,” Carragher told MNF.“Mourinho has had so much thrown at him recently; accusations that he’s yesterday’s man, his football is from a different era. I’d love to see him win again and almost stick two fingers up at pundits and the press, whoever.“It would be a good story for Mourinho to do that again. After what he’s achieved in his career, he still gets a lot of criticism because he rubs people up the wrong way at different times, but it would be nice to see him win again in a different way.”Carragher added: “There was no bigger fan of Mauricio Pochettino than me, but his team was done, and it needed to evolve and change.“When Jose came in things were a bit stop-start last season, and don’t think for one minute that anyone involved with Tottenham – from Daniel Levy, to Jose Mourinho and his players – thought about challenging for the title this season, it would have all been about getting into the top four.“But because this season has been so strange – Liverpool losing Virgil van Dijk, Manchester City not looking right and having already dropped eight points – if there is ever going to be a chance when someone does do something, this will be the season.” FREE TO WATCH: Highlights from Leicester’s win over Wolves in the Premier League Tottenham head coach Jose Mourinho believes his side ‘could be champions in many European countries’ after Spurs briefly topped the table following their 1-0 win at West Brom “Alan Shearer is definitely the best striker in PL history in terms of his goal record. He’s the best striker I’ve played with for England, in terms of a number nine, and Rooney I’d put up there with him.And Harry Kane has so much similarity in his game, in terms of the mentality, just ice cold, doesn’t seem to flinch if he misses a chance, flinch if a goalkeeper saves one, he’ll come back and do the right thing. Scoring a goal is a process for them, where he knows where the target is.“It’s methodical, and he’s brilliant. He’s a great professional, and England are lucky to have him.” I don’t think they can win the league, I really don’t, but because Jose Mourinho is there, there will be an element of thinking he can do the unthinkable.Gary Neville on Spurs’ title chances on MNF – Advertisement – – Advertisement – Just pipping Spurs at the top of the Premier League heading into the international break is Leicester following their 1-0 win against Wolves on Sunday.Neville was full of praise for the job Brendan Rodgers is doing at the King Power Stadium, calling him ‘one of the outstanding managers in the league’.“They are an awkward, awkward proposition,” Neville said on his podcast. “They do a lot of things very well, they’re efficient, well coached. They started last season well but fell away at the end. 0:32 It was the first time they had hit the summit since August 2014, before Leicester leapfrogged them into top spot later in the day. 2:53 FREE TO WATCH: Highlights from Tottenham’s win over West Brom in the Premier League “They go behind, and I think United deservedly came out on top in the end.“They’re just so inconsistent. If you think about the last week, the performance against Leipzig, PSG, against Arsenal, in Turkey, they’ve got to get rid of that, it’s up and down.“It’s a thing that will always put them under pressure as players and a manager. You need consistency, ultimately that’s what a champion needs to be, and at the moment they’re inconsistent.” 2:51 “It’s an outstanding performance from Brendan Rodgers. Wolves are a very difficult customer to get past, and what Leicester are doing is outstanding.“It proves it’s no one-season wonder,” he added. There’s continuity now, and Brendan Rodgers is one of the outstanding managers in the league.“We talk about British coaches not being at the level of Jurgen Klopp, Pep Guardiola, Jose Mourinho or Mauricio Pochettino, but actually Rodgers, who has finished second with Liverpool and done what he’s done with Leicester, is up there really. He’s a fantastic coach.”‘Man Utd so inconsistent’ Spurs remain second heading into the international break and there is building optimism at the club, that they can mount a serious title challenge and win a first Premier League title and a first league championship since 1961.Despite Neville’s doubts about their title credentials, he thinks it would be one of the great football stories if a resurgent Mourinho could lead Spurs to the title.“I said a couple weeks ago on Monday Night Football that Spurs couldn’t win the league, and I still don’t think they can,” he told The Gary Neville Podcast.“But I do agree with Jamie Carragher that it would be the most outstanding story to see Jose Mourinho win the Premier League with Tottenham. 1:11 FREE TO WATCH: Highlights from Manchester United’s win over Everton in the Premier League Kane’s remarkable numbersKane scored his 150th Premier League goal against West Brom after scoring his 200th Tottenham goal on Thursday.The striker has scored eight goals in his eight Premier League appearances against West Brom, one of nine sides he averages a goal-per-game or better against in the competition.Kane has 13 goals and 10 assists in 14 matches in all competitions for Spurs this season.The England captain has been directly involved in 13 goals in his last six away Premier League games (7 goals, 6 assists).Kane has scored 33 goals in his last 31 Premier League starts against newly promoted teams.Only Alan Shearer (212) and Sergio Aguero (217) scored their 150th Premier League goal in fewer appearances than Kane, who has done so in his 218th match in the competition. Image:Harry Kane celebrates his winner at The Hawthorns
“Recently government-imposed travel restrictions have effectively stifled any hope of a stable and progressive recovery, Norwegian has been hit from all sides by factors outside of our control,” said Norwegian chief executive, Jacob Schram. “This is a sad day for everyone at Norwegian and I sincerely apologise to all our colleagues that are now affected, but there is no other alternative.”He added: “Prior to Covid-19, Norwegian employed more than 10,000 people, but the coming months there will be only 600 colleagues employed. – Advertisement – Norwegian argues its operations are unsustainable in light of travel restrictions imposed in the wake of the Covid-19 pandemic which actively discourage passengers from travelling. The consequences of the government-imposed travel restrictions are critical and Norwegian needs to keep its running costs to a minimum, while the company continues to work on solutions to survive.“Following the disappointing announcement from the government, we have no choice but to furlough an additional 1,600 colleagues and park 15 of the 21 aircraft we have operated the past months. – Advertisement – OlderServiced apartments weather Covid-19 storm in Europe “Our goal is to keep six aircraft on domestic routes in Norway, and I expect that Norwegian will also receive route support from the ministry of transportation, as previously announced.”Norwegian will continue to operate a small number of routes, from Oslo to Alta, Bergen, Bodø, Evenes, Haugesund, Kirkenes, Molde, Stavanger, Tromsø, Trondheim and Ålesund.Flights will also operate on the Tromsø-Longyearbyen route. Norwegian has furloughed a further tranche of employees and announced new reductions in capacity.The decision follows a move by the government of Norway to deny the low-cost carrier further financial support yesterday.- Advertisement – – Advertisement –
Fitness buffs are turning to India’s open-air wrestling pits for safe workout options during the pandemic. Gyms have reopened and are taking precautions – such as regularly sanitising, maintaining social distancing and making masks compulsory for staff. But customers are yet to return in large numbers. – Advertisement – Case numbers continue to climb in India and especially in the capital Delhi, which in recent days has been recording its highest daily tallies so far. So traditional open-air wrestling pits, which are a a feature of many cities, have grown in popularity.- Advertisement – – Advertisement –
Ras Al Khaimah has been named the Gulf Tourism Capital for 2021 at the fifth annual meeting of tourism ministers of the Gulf Cooperation Council. – Advertisement –
Jan 13, 2005 (CIDRAP News) As a result of a federal court ruling that stopped the US military’s anthrax vaccination program last October, the Food and Drug Administration (FDA) is asking for public comments on its finding that the anthrax vaccine is safe and effective. A week after the ruling, the FDA responded with a statement, based on the findings of an expert panel in 1985 and subsequent research, that the vaccine is safe and effective for all forms of anthrax. In response, Sullivan lifted his injunction against the DoD vaccination program. But in October 2004, Sullivan said that the FDA had failed to follow its own rules in not soliciting public comments before confirming (in December 2003) that the vaccine is approved for all forms of anthrax. Citing a 1998 law that bars DoD from forcing military members to take drugs not approved for their intended use, Sullivan said military personnel could not be forced to receive anthrax shots without a special presidential order. DoD then suspended the vaccination program. In the notice, the FDA concedes that the 1950s clinical trial data on which its licensing decisions were largely based included too few cases of inhalational anthrax to show clearly that the vaccine prevents that disease. But the notice says the trial data show that the vaccine’s efficacy against all types of anthrax combined was 92.5%. In 1985, an FDA expert panel recommended confirming the approval of the anthrax vaccine, along with various other bacterial vaccines and toxoids. In December 1985, FDA proposed to confirm the approvals and gave the public 90 days to comment on them. The agency received no specific comments on AVA at the time. AVA, also called BioThrax, is made by BioPort Corp. of Lansing, Mich. HHS announced last November that it planned to buy 5 million doses of the vaccine for potential civilian use. HHS also has contracted with VaxGen, Inc., to produce 75 million doses of a new, not-yet-licensed anthrax vaccine that officials hope will require fewer doses and have fewer side effects than the existing vaccine. The existing vaccine requires six doses over 18 months, followed by annual boosters. Last month, DoD officials asked the Department of Health and Human Services (HHS) for emergency authority to resume the vaccination program because of what they said was an increased risk of anthrax attacks on US forces. HHS officials were still reviewing that request as of yesterday, Marc Wolfson of the HHS Office of Public Health Emergency Preparedness told CIDRAP News. A federal judge in Washington, DC, ruled in December 2003 and again in October 2004 that the FDA acted improperly in authorizing the use of the anthrax vaccine to prevent inhalational anthrax, as distinguished from cutaneous anthrax. The military vaccination program has been on hold since the October ruling. The FDA rules that Sullivan said the agency ignored went back to 1972, when the FDA took over the licensing of drugs and vaccines from the National Institutes of Health (NIH). The FDA then set up a procedure for reviewing products that had been licensed by the NIH. The procedure included reviews by independent expert panels and inviting public comments before confirming the product approvals. The FDA notice is the latest chapter in a dispute between the government and military personnel who are fighting the anthrax vaccination program because of concern about side effects. Since 1998, about 1.25 million Department of Defense (DoD) personnel, mostly those serving in the Middle East and Korea, have received the vaccine. But some have resisted the shots and been disciplined or forced out of the military as a result. The two court rulings came in a lawsuit filed by six military members and civilian contractor personnel. In the first ruling, in December 2003, US District Judge Emmet G. Sullivan concluded that AVA had never been specifically approved or labeled for use against inhalational anthrax, which is the form the military is most concerned about. In the controlled trial, called the Brachman study, 1,249 workers at four textile mills that processed goat hair received either AVA, a placebo, or no treatment. Five cases of inhalation anthrax occurred in the trial, all in unvaccinated workers. There also were 21 cases of cutaneous anthrax, all but three of them in unvaccinated workers. The agency concludes that the vaccine label doesn’t need to state what route of anthrax exposure the vaccine is intended for. “We propose the indication section of the labeling for AVA [Anthrax Vaccine Adsorbed] not specify the route of exposure, and the vaccine be indicated for active immunization against Bacillus anthracis, independent of the route of exposure,” the notice states. In the Federal Register notice, the FDA describes the 1950s clinical trial of AVA and later epidemiologic data on the vaccine’s efficacy and safety. In an effort to overcome the court’s objections, the FDA on Dec 29 quietly published a Federal Register notice explaining its proposal to reaffirm the vaccine’s approval and also inviting the public to comment on the matter. The deadline for comments is Mar 29. The notice also cites some epidemiologic data in support of the FDA proposal to reconfirm the AVA approval. The Centers for Disease Control and Prevention collected data on anthrax cases in industrial settings from 1962 to 1974 and also monitored adverse reactions to the vaccine in about 7,000 at-risk workers from 1967 to 1971. From the latter study, the expert panel concluded that the vaccine was “fairly well tolerated” and that severe local reactions and systemic reactions were “relatively rare.” Also in support of the vaccine, the FDA notice cites a small clinical study conducted by DoD after 1985 and data collected by the Vaccine Adverse Event Reporting System. In addition, the report cites the 2002 analysis by the Institute of Medicine, which found that the vaccine was “acceptably safe” and effective against inhalational and other forms of anthrax. The 1985 expert panel said that ethical concerns and the low incidence of anthrax make it impossible to conduct further controlled clinical trials of the vaccine, according to the notice. The expert panel concluded that the vaccine provided 93% protection overall but that cases of inhalational anthrax were too few to assess the vaccine’s effect against that form of anthrax, the Federal Register notice says. According to Sullivan’s October 2004 ruling, the FDA never followed up with specific confirmation of the AVA licensing until after his December 2003 ruling. When the FDA then said the vaccine was effective for all forms of anthrax, it relied partly on post-1986 research findings, on which the public never had a chance to comment, according to the judge. “FDA agrees that the five cases of inhalation anthrax reported in the course of the Brachman study are too few to support an independent statistical analysis,” the notice states. But it adds that the study included all types of anthrax, the overall efficacy of the vaccine was 92.5%, and no inhalational cases occurred in vaccinated workers. Therefore, the FDA proposes to label the vaccine for anthrax immunization without specifying the route of exposure.
Acambis and Bavarian Nordic said the Department of Health and Human Services (HHS) has requested proposals to supply the attenuated vaccine called modified vaccinia Ankara, or MVA. Both companies have developed versions of MVA. See also: Peter Wulff, president and CEO of Copenhagen-based Bavarian Nordic, said in a news release, “With this tender, the US government has committed itself to protect the 25% of the population who cannot safely be given current smallpox vaccines. The world market for a safe smallpox vaccine has now been opened, since governmental authorities in the larger European countries will naturally undertake a similar commitment as the American authorities.” Aug 16, 2005 (CIDRAP News) – The US government has called for proposals to supply up to 80 million doses of a weakened smallpox vaccine to protect people for whom the conventional vaccine is too risky, according to two vaccine manufacturers. The vaccine is intended for use in people who face an increased risk of serious reactions to the conventional vaccine, such as children, pregnant women, and people with immune system disorders or eczema. The federal government has stockpiled hundreds of millions of doses of the conventional vaccine over the past few years. The MVA contracts will be funded under Project Bioshield, a program enacted last year to support the development of medical defenses against biological, chemical, and radiological weapons, according to Marc Wolfson, spokesman for the HHS Office of Public Health Emergency Preparedness in Washington DC. Aug 16 Bavarian Nordic news releasehttp://www.bavarian-nordic.com/investor/announcements/2005-29.aspx http://www.cidrap.umn.edu/cidrap/content/bt/smallpox/news/safevax.html Federal officials have set a Sep 29 deadline for receiving company proposals and plan to award one or more contracts in February 2006, according to Acambis and Bavarian Nordic. CIDRAP News stories on previous MVA contracts awarded to Acambis and Bavarian Nordichttp://www.cidrap.umn.edu/cidrap/content/bt/smallpox/news/oct042004smallpox.html Acambis said it launched a phase 2 clinical trial of MVA3000 in 700 healthy adults last month. A phase 1 study yielded good results for safety and immunogenicity, with 97% of subjects who were vaccinated at the highest dose showing antibodies specific to the vaccinia virus, the company said. Existing smallpox vaccines are made with live vaccinia virus, which in rare cases can cause serious or life-threatening side effects such as a severe rash or encephalitis. MVA is a strain of vaccinia that cannot replicate inside human cells and cause a spreading infection, according to HHS. Wolfson said he couldn’t give an estimate of the cost of the MVA vaccine stockpile. But a Reuters report said investment analysts estimated that the full 80 million doses could be worth more than $1.2 billion. The earlier contracts required the companies to test the vaccines in animals, begin clinical trials, and develop plans for mass production. Acambis is collaborating with Baxter Healthcare to manufacture MVA3000. Editor’s note: This story was revised Aug 17 to add information on funding and a link to the government’s request for proposals to supply the vaccine. HHS wants to obtain 20 million doses of MVA within 2 years after awarding a contract and to have an option to buy another 60 million doses in the future, according to a news release from Acambis, based in the United Kingdom. The HHS is also calling for vaccine suppliers to conduct clinical trials and obtain a federal license for their vaccine. Both companies have been developing their versions of MVA under contracts awarded by the National Institute of Allergy and Infectious Diseases in February 2003 and September 2004. Acambis’s vaccine is called MVA3000, and Bavarian Nordic’s is Imvamune.
Dec 30, 2005 (CIDRAP News) – New outbreaks of avian influenza in birds were reported this week in Romania and Turkey, but wild birds that died mysteriously in Malawi in southern Africa were found to be free of flu viruses.Tests in Britain detected H5N1 viruses in seven samples sent from four areas in southeastern Romania, according to an Agence France-Presse (AFP) report published yesterday. The story did not specify what kinds of birds were involved.Authorities had ordered the precautionary culling of birds in the affected areas after initial tests pointed to an H5 virus, AFP reported.With the latest findings, the deadly virus has been detected in 22 Romanian localities since early October, the story said. More than 100,000 poultry and other birds have been slaughtered to contain the disease since then.In Turkey, poultry in the eastern province of Igdir, near the Armenian border, tested positive for an H5 virus, but it was not yet known whether it was the deadly H5N1 strain, according to a Dec 27 AFP report.About 1,200 birds died in the area in mid-December, and another 350 were culled as a precaution, the story said. An agricultural official said samples from the latest outbreak had been sent to Britain for testing.If confirmed, the latest finding would represent Turkey’s second outbreak of H5N1, according to the story. The first one was discovered Oct 5 on a turkey farm in Balikesir province in western Turkey.In Malawi, the government said tests in South Africa found no avian flu virus in samples from migratory birds that died mysteriously about 2 weeks ago, according to a report published by the Chinese news service Xinhua and carried by ProMED-mail.Thousands of birds called fork-tailed drongos had died on a hill in the central district of Ntchisi, the story said. The tested samples showed “no presence of avian influenza,” said Ben Chimera, chair of the country’s Avian Influenza Technical Committee.Chimera said the cause of the birds’ death remained unknown, but he added that they might have died because of heavy rains in the area.In other developments, another suspected human case of avian flu was reported in Indonesia today, according to an AFP story carried by the Jakarta Post.A local health official was quoted as saying a 48-year-old man died 10 hours after he was admitted to a hospital in the central Java town of Magelang with a high fever and respiratory problems.Blood samples were sent to Jakarta for testing, and samples would also be sent to Hong Kong for tests, the story said.